Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C40H63N15O13 |
| Molecular Weight | 962.0209 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCC(O)=O)NC2=O)C(C)C
InChI
InChIKey=JXPWLIYXIWGWSA-CLBRJLNISA-N
InChI=1S/C40H63N15O13/c1-19(2)31-38(67)51-23(8-11-29(42)58)34(63)53-26(17-56)39(68)55-14-4-6-27(55)37(66)50-24(9-12-30(59)60)33(62)52-25(15-20-16-45-18-47-20)36(65)49-22(7-10-28(41)57)32(61)48-21(35(64)54-31)5-3-13-46-40(43)44/h16,18-19,21-27,31,56H,3-15,17H2,1-2H3,(H2,41,57)(H2,42,58)(H,45,47)(H,48,61)(H,49,65)(H,50,66)(H,51,67)(H,52,62)(H,53,63)(H,54,64)(H,59,60)(H4,43,44,46)/t21-,22-,23-,24-,25-,26-,27-,31-/m0/s1
| Molecular Formula | C40H63N15O13 |
| Molecular Weight | 962.0209 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:11:04 UTC 2023
by
admin
on
Sat Dec 16 17:11:04 UTC 2023
|
| Record UNII |
9VHD7J6363
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
603317
Created by
admin on Sat Dec 16 17:11:05 UTC 2023 , Edited by admin on Sat Dec 16 17:11:05 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000181117
Created by
admin on Sat Dec 16 17:11:05 UTC 2023 , Edited by admin on Sat Dec 16 17:11:05 UTC 2023
|
PRIMARY | |||
|
9VHD7J6363
Created by
admin on Sat Dec 16 17:11:05 UTC 2023 , Edited by admin on Sat Dec 16 17:11:05 UTC 2023
|
PRIMARY | |||
|
57341282
Created by
admin on Sat Dec 16 17:11:05 UTC 2023 , Edited by admin on Sat Dec 16 17:11:05 UTC 2023
|
PRIMARY | |||
|
1088543-62-7
Created by
admin on Sat Dec 16 17:11:05 UTC 2023 , Edited by admin on Sat Dec 16 17:11:05 UTC 2023
|
PRIMARY | |||
|
DB15188
Created by
admin on Sat Dec 16 17:11:05 UTC 2023 , Edited by admin on Sat Dec 16 17:11:05 UTC 2023
|
PRIMARY | |||
|
C174590
Created by
admin on Sat Dec 16 17:11:05 UTC 2023 , Edited by admin on Sat Dec 16 17:11:05 UTC 2023
|
PRIMARY | |||
|
10715
Created by
admin on Sat Dec 16 17:11:05 UTC 2023 , Edited by admin on Sat Dec 16 17:11:05 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> DERIVATIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
AIMS: To explore the safety, pharmacokinetics and pharmacodynamics in humans of the unacylated ghrelin analogue AZP-531 designed to improve glycemic control and reduce weight.
FINDINGS: AZP-531 was well tolerated. Single and multiple-dose PK parameters were similar. Maximal AZP-531 concentrations were typically reached at 1h post-dose. Cmax and AUC were dose-proportional. Mean t1/2 was 2-3h. In Part B, AZP-531 15undefinedg/kg and above significantly improved glucose concentrations, without increasing insulin levels, suggesting an insulin-sensitizing effect. AZP-531 decreased mean body weight by 2.6kg (vs 0.8kg for placebo). In Part C, glucose parameters improved in all groups, including placebo, suggesting a study effect in uncontrolled patients at baseline. Notwithstanding, AZP-531 60undefinedg/kg reduced HbA1c by 0.4% (vs 0.2% for placebo) and body weight by 2.1kg (vs 1.3kg for placebo).
CONCLUSION: AZP-531 was well tolerated in this first-in-human study. Its pharmacokinetic profile, suitable for once-daily dosing, and metabolic effects support further clinical development for type 2 diabetes.
|
